Upstream Bio, Inc. (UPB) Stock Grade

About Upstream Bio, Inc.'s fundamentals

Upstream Bio is a biotechnology company with a market capitalization of $288.4 million that is experiencing strong revenue growth at 20.4% year-over-year. However, the company is currently unprofitable, reporting a net loss in its latest annual statement with a net margin of -5026.0%, indicating substantial operating losses relative to its revenue base. The company does not pay a dividend and lacks positive return on equity metrics, which is typical for early-stage biotech firms still in development phases. Investors should note that profitability metrics and traditional valuation ratios like P/E ratio are not meaningful given the company's current loss-making status.